MAGDALENA ATONDO FRANCO: Open Payments
NPI 1275117814 · LAMONT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,096 in 132 payments from 20 companies in 2025. Trend: 2023 $698 · 2024 $1,423 · 2025 $2,096
Food & beverage: $2,024Education: $72
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 45 | $568 |
| Janssen Biotech, Inc. | 15 | $254 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 10 | $175 |
| GENZYME CORPORATION | 6 | $168 |
| Incyte Corporation | 19 | $167 |
| Amgen Inc. | 9 | $142 |
| UCB, Inc. | 4 | $82 |
| Smith+Nephew, Inc. | 2 | $71 |
| E.R. Squibb & Sons, L.L.C. | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
Products named: SKYRIZI, TREMFYA, DUPIXENT, OPZELURA, RINVOQ, Otezla, Winlevi, Bimzelx.
Industry payments across CA — which companies pay providers there.
